Autoplaque vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by Cedars-Sinai Medical Center: AIM

EchoNext

by Pathway Labs

AI Verdict

Autoplaque and EchoNext are adjacent tools in cardiology AI, both FDA-cleared and focused on heart health. Autoplaque specializes in quantitative analysis of coronary plaques and luminal stenoses from CT angiography images for heart attack risk, while EchoNext analyzes standard ECGs to detect hidden structural heart disease like heart failure and valve disease. The choice between them depends on whether the need is for detailed plaque analysis via CT or broad structural heart disease screening via ECG.

Choose Autoplaque if…

Choose Autoplaque if your primary need is detailed, AI-powered quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. This tool is ideal for cardiologists and radiologists who require precise measurements and characterization of atherosclerotic plaque to aid in heart attack risk prediction and treatment guidance, offering automated segmentation and comprehensive review capabilities on a workstation.

View Autoplaque →

Choose EchoNext if…

Choose EchoNext if you need an AI tool to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This tool is best suited for broad access screening in various clinical settings, from major hospitals to community practices, to identify high-risk patients who may require further evaluation with an echocardiogram.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	EchoNext
Pricing	Not disclosed	Starts at $600/month
Deployment	Workstation-based software, runs on Windows or Mac computer platforms	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Autoplaque is a workstation-based software that runs on Windows or Mac, offering clinicians direct control over reviewing and editing segmentations. EchoNext is available through the OpenEvidence clinical decision support platform, suggesting integration into existing workflows. Without further details on the user interfaces or specific workflow integrations, it's difficult to definitively declare a winner in usability.

Clinical Value

EchoNext

EchoNext demonstrates superior clinical value by detecting hidden structural heart disease from routine ECGs, outperforming cardiologists in diagnostic accuracy and potentially leading to earlier, life-saving interventions like heart transplants. Autoplaque offers quantitative analysis of coronary plaques from CT angiography, aiding in risk prediction, but EchoNext's ability to screen broadly and identify previously undiagnosed high-risk conditions from a readily available test presents a more significant clinical impact.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, including details on implementation fees and discounts, making its value proposition clear. Autoplaque's pricing is not disclosed, which makes it impossible to assess its value in comparison. The transparency of EchoNext's pricing gives it an advantage in this dimension.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating strong enterprise integration and scalability. It also offers a BAA and HIPAA compliance. Autoplaque is workstation-based and lacks disclosed information on BAA or HIPAA compliance, suggesting a potentially more limited enterprise deployment.

Innovation

EchoNext

EchoNext represents a significant innovation by being the world's first FDA-approved AI tool to detect hidden structural heart disease from standard ECGs, a widely accessible and inexpensive test. This capability allows for broad screening and early detection of conditions often missed. Autoplaque's AI-powered quantitative analysis of CT angiography images is valuable but builds upon existing imaging modalities, making EchoNext's approach more disruptive in its diagnostic paradigm.

Support & Docs

Tie

Neither Autoplaque nor EchoNext explicitly detail their customer support channels or the extent of their documentation in the provided information or web searches. While Autoplaque mentions a user manual specifying hardware, and EchoNext has a publicly released dataset and model weights, there's insufficient information to differentiate their support and documentation offerings comprehensively.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	EchoNext
Name	Autoplaque	EchoNext
Company	Cedars-Sinai Medical Center: AIM	Pathway Labs
Description	Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features (Analysis Type)	AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Autoplaque and EchoNext integrate into existing clinical workflows and EHR systems?

Autoplaque is a workstation-based post-processing application designed to run on Windows or Mac platforms, allowing clinicians to review and edit AI-generated segmentations of vessels, plaque, and lumen. While it processes DICOM image data from a local hard drive, specific details on its integration with EHR systems are not provided. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, suggesting a more integrated approach for broad access and streamlined workflow within existing clinical decision support pathways.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Autoplaque provides AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, with studies showing excellent correlation with intravascular ultrasound for noncalcified plaque volumes and high agreement for total plaque volume, non-calcified volume, calcified plaque volume, and diameter stenosis. EchoNext analyzes standard ECGs to detect hidden structural heart disease, demonstrating superior diagnostic accuracy compared to expert cardiologists, with an AUROC of 85% in internal tests and 78-80% in external validation. In studies, EchoNext accurately identified 77% of structural heart problems from ECGs alone, compared to 64% for cardiologists.

What is the typical learning curve for physicians to effectively use Autoplaque and EchoNext?

Autoplaque is a semi-automated system that requires user interaction and is intended for use by trained medical professionals, including radiologists and cardiologists, who have been appropriately trained in its functions. The system allows for clinician review and editing of automated segmentations, suggesting a degree of user involvement in the analysis process. EchoNext is an AI-powered ECG analysis tool designed to be integrated into clinical decision support platforms, which may imply a focus on ease of interpretation of its risk scores rather than extensive manual operation.

What kind of support and training are available for physicians using these tools?

For Autoplaque, it is stated that users should be appropriately trained in the software's functions, capabilities, and limitations, and that typical users are trained medical professionals. Specific details about ongoing support quality or formal training programs are not explicitly provided in the given information. For EchoNext, while not explicitly detailed, its deployment through the OpenEvidence clinical decision support platform suggests that support might be integrated within that platform's existing framework.

What are the audit trail features for each tool to ensure transparency and accountability in AI-assisted diagnoses?

The provided information does not explicitly detail the audit trail features for either Autoplaque or EchoNext. However, in general, robust cloud security frameworks, which EchoNext utilizes through its deployment on OpenEvidence, often include features like cloud logging and Security Information and Event Management (SIEM) that align with audit requirements. Autoplaque's workstation-based nature suggests that audit trails would be managed locally.

What are the considerations for rolling out these tools across multiple clinical sites or a large healthcare system?

Autoplaque is a workstation-based software, meaning each site would likely require individual installations on Windows or Mac computer platforms, and users would need to ensure suitable monitor quality and ambient light conditions. This may involve a more decentralized rollout strategy. EchoNext, being available through the OpenEvidence clinical decision support platform, is designed for broad access, from major hospitals to community practices, suggesting it is well-suited for multi-site deployment through a centralized platform.

In what clinical contexts would a physician choose Autoplaque over EchoNext, or vice versa?

A physician would likely choose Autoplaque when their primary need is detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images for heart attack risk prediction and treatment guidance, especially if they prefer a workstation-based solution with the ability to review and edit AI-generated segmentations. Conversely, a physician would likely choose EchoNext for broad screening to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, particularly in settings where a cost-effective, non-invasive screening tool is needed to identify patients who require further imaging like echocardiography.